scholarly journals Evaluation of Liquid Biopsy in Patients with HER2-Positive Breast Cancer

2021 ◽  
Vol 2021 ◽  
pp. 1-5
Author(s):  
Jianguo Huai ◽  
Ming Cao ◽  
Yan Jiang ◽  
Xiaomiao Yang ◽  
Yanyan Zhu ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Real Time ◽  
Peripheral Blood ◽  
Liquid Biopsy ◽  
Hot Spot ◽  
Her2 Status ◽  
Time Interval ◽  
Her2 Positive ◽  
Her2 Positive Breast Cancer ◽  
Positive Breast Cancer

Breast cancer is one of the common malignant tumors, and liquid biopsy has become a hot spot for clinical testing. To clarify the detection effect of liquid biopsy in breast cancer, we collected peripheral blood of HER2-positive (human epidermal growth factor receptor 2-positive) patients. Circulating tumor cells (CTCs) were isolated and analyzed. HER2 expression on CTCs was detected. The results showed that in the 198 HER2-positive samples, the CTC detection rate was 79.8% (158/198), and the mean number of CTCs was 21, ranging from 1 to 63/7.5 mL peripheral blood. Only 41.1% (65/158) of patients had histology and CTC HER2 status consistent with the remaining 58.9% (93/158) of patients, although their histological HER2 was positive, and CTC HER2 was negative. Our study confirmed the value of CTC HER2 real-time status testing in HER2-positive breast cancer patients. The inconsistency in HER2 status between CTCs and histology may be related to the time interval between CTCs and histological HER2 detection, suggesting that real-time HER2 detection is necessary for histological HER2-positive patients.

Quantification of intratumoral heterogeneity of HER2 status in breast cancer.

2017 ◽  
Vol 35 (15_suppl) ◽  
pp. 1036-1036
Author(s):  
Rie Horii ◽  
Masaaki Matsuura ◽  
Hiro Nitta ◽  
Yoshinori Ito ◽  
Shinji Ohno ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Tumor Cells ◽  
Intratumoral Heterogeneity ◽  
Gene Copy ◽  
Her2 Status ◽  
Her2 Gene ◽  
Her2 Positive ◽  
Her2 Positive Breast Cancer ◽  
Protein Status ◽  
Positive Breast Cancer

1036 Background: Intratumoral heterogeneity (ITH) occurs as a consequence of epigenetic aberrations in tumor cells with genetic diversity. HER2 ITH can be classified into genetic (a mixture of tumor cells with and without HER2 gene amplification) and epigenetic ITH (a mixture of HER2 gene-amplified tumor cells with and without HER2 protein overexpression). However, the both effects of genetic and epigenetic ITH on HER2-targeted therapy have not been clearly demonstrated. In order to implement ITH as a referenced factor for treatment selection, the ITH quantification is necessary. Gene-protein assay (GPA), in which immunohistochemistry and dual in situ hybridization are simultaneously performed on a single slide, allows bright-field analyses of both gene and protein status. We aimed to quantify HER2 ITH by the combination of gene and protein status and clarify its clinical significance. Methods: Fifty three patients with HER2-positive breast cancer, who underwent neoadjuvant trastuzumab with chemotherapy, were examined. Five representative microscopic images were captured from a GPA slide of a pre-therapeutic biopsy material. All evaluable tumor cells in the images were scored according to the HER2 status determined by the combination of gene copy number and protein expression (Table). We investigated the relationship between the HER2 scores and pathological complete response (pCR) to the neoadjuvant treatment by the logistic analysis. Results: The average of HER2 scores, indicating the degree of the HER2 status, varied from 2.21 to 5.98. It was significantly related to pCR (Estimate: 1.21, Std. error: 0.46, RR: 3.34, P=0.009, 95%CI: 1.35-8.25). The standard deviation of HER2 scores, indicating the degree of the HER2 ITH, varied from 0.13 to 1.37. It was significantly related to pCR (Estimate: -2.09, Std. error: 0.83, RR: 0.12, P=0.012, 95%CI: 0.02-0.63). Conclusions: HER2 ITH, quantified by GPA, is a predictive factor for the therapeutic effect to trastuzumab-based treatment in HER2-positive breast cancer. [Table: see text]

scholarly journals The first results of the national programme for the diagnosis and treatment of HER2-positive breast cancer in Turkmenistan

2018 ◽  
Vol 20 (2) ◽  
pp. 42-44
Author(s):  
M B Berdimyradova ◽  
S M Khadjiev ◽  
D N Khommadova ◽  
G O Polatova ◽  
A O Kakajanova ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Survival Rates ◽  
Diagnosis And Treatment ◽  
Her2 Status ◽  
Advanced Stage ◽  
Her2 Positive ◽  
Her2 Positive Breast Cancer ◽  
First Results ◽  
Advanced Stage Cancer ◽  
Positive Breast Cancer

Abstract The article deals with the changes in diagnosis and treatment of early and advanced HER2-positive breast cancer (BC) in Turkmenistan during 2010-2018. Early BC detection programme started in Turkmenistan in the year 2010 and the percentage of stage I-II BC detection in the country increased by 8.8% and reached 69.6% in 2017. Automated HER2-testing method in diagnostic breast tumors was carried out in December 2016; the number of immunohistochemical studies was increased in 2 times from December 2016 to December 2017 and the percentage of HER2 status assessment in patients with newly diagnosed disease reached 99%. The central programme of targeted therapy for HER2-positive BC with trastuzumab and pertuzumab, first in patients with advanced-stage cancer, and then in patients with early HER2-positive BC started within the country in 2016. The first results of the application of anti-HER2 therapy in Turkmenistan of advanced-stage cancer showed promising results: the higher clinical efficacy and favourable safety profile in the treatment. The first results of anti-HER2 blockade in the neoadjuvant chemotherapy confirmed the high percentage of the complete morphological regression in HER2-positive BC, and gave us hope for the future associated with higher survival rates.

scholarly journals Liquid biopsy identifies actionable dynamic predictors of resistance to Trastuzumab Emtansine (T-DM1) in advanced HER2-positive breast cancer

2021 ◽  
Vol 20 (1) ◽  
Author(s):  
Matteo Allegretti ◽  
Alessandra Fabi ◽  
Elena Giordani ◽  
Cristiana Ercolani ◽  
Paolo Romania ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Liquid Biopsy ◽  
Trastuzumab Emtansine ◽  
Her2 Positive ◽  
Her2 Positive Breast Cancer ◽  
Positive Breast Cancer

Expression of hormone receptors ERα, ERβ and PgR in HER2-positive breast cancers

2006 ◽  
Vol 24 (18_suppl) ◽  
pp. 10525-10525
Author(s):  
M. Litwiniuk ◽  
V. Filas ◽  
J. Moczko ◽  
R. Kaleta ◽  
J. Breborowicz
Keyword(s):  
Breast Cancer ◽  
Hormone Receptors ◽  
Detection System ◽  
Statistical Significance ◽  
Her2 Status ◽  
Breast Cancers ◽  
Breast Cancer Patients ◽  
Her2 Positive ◽  
Her2 Positive Breast Cancer ◽  
Positive Breast Cancer

10525 Background: HER-2/neu gene is amplified and overexpressed in 15–20% of invasive breast cancers. HER2-positive breast cancers have a worse prognosis than HER2-negative tumors and distinctive clinical features. They express hormone receptors for estrogen (ERα) and for progesterone (PgR) less frequently than HER2-negative tumors. The identification of the other human estrogen receptor, receptor beta (ERβ), raises a question of ERβ occurrence in HER2-positive breast cancer. Patients and methods: Formalin-fixed, paraffin embedded tissues from 90 patients with invasive HER2-positive breast cancer and from 99 patients with HER2-negative breast cancer were used in this study. The HER2 status was analyzed using HercepTest TM (IHC), and IHC 2+ results were confirmed with FISH test. Immunostaining for ERα, ERβ and PgR was performed using monoclonal antibodies against ERα, PgR (DakoCytomation) and against ERβ (CHEMICON). The EnVision detection system was applied. The data were analyzed using nonparametric Fisher-Freeman-Halton test; the statistical significance was considered when p < 0.5. Results: Only 33% of the HER2-positive breast cancers were ERα-positive compared with 63% in the HER2-negative group (p < 0.001). The expression of ERβ protein was observed in almost equal frequency in both groups (57% of HER2-positive breast cancers and 57.7% of HER2-negative tumors, p = 0.889). The expression of PgR was observed in 30% of HER2-positive breast cancers and in 68.7% of HER2-negative tumors (p < 0.001). Conclusion: The expression of ERβ (unlike that of ERα and PgR) was similar in HER2-positive and in HER2-negative breast cancers. Thus, ERβ may be a potential target in future endocrine therapy for women with HER2-positive breast cancers. No significant financial relationships to disclose.

Biology and prognosis of 1,685 recently diagnosed HER2-positive breast carcinomas

2006 ◽  
Vol 24 (18_suppl) ◽  
pp. 10501-10501
Author(s):  
S. Ménard ◽  
S. De Placido ◽  
S. Scalone ◽  
A. Molino ◽  
M. Mottolese ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Relapse Rate ◽  
Hormone Receptors ◽  
Low Frequency ◽  
Her2 Status ◽  
Breast Carcinomas ◽  
Her2 Positive ◽  
Her2 Positive Breast Cancer ◽  
Relapse Rates ◽  
Positive Breast Cancer

10501 Background: Understanding biology, prognosis and drug-sensitivity of HER2-positive breast cancer might help optimization of treatment of patients affected by this type of cancer. Most available studies are retrospective and suffer from the low frequency of this tumor subset. Methods: We conducted a large national retrospective/prospective study involving 1685 patients (cases) with HER2-positive (2+, 3+ score) primary breast carcinomas diagnosed in Italy in 2000/2001; for each case, in each participating center, a control was identified as the first consecutive patient with HER2-negative cancer (0, 1+ score). Results: In addition to the already known association with some pathologic parameters such as grade, hormone receptors, and ductal histotype, the four HER2 categories also displayed specific features, for example, a significantly higher frequency of p53-positivity among HER2–2+ tumors than in the other three categories, and a significantly lower frequency of lymphoid infiltration and desmoplasia, accompanied by a higher frequency of vascular invasion, in HER2–1+ as compared to HER2–0 tumors. Neither tumor size nor nodal involvement were associated with HER2 status. With a median follow-up of 4 yrs, the HER2-positive group showed a 20% relapse rate versus 14% in the HER2-negative group (p < 0.001). Analysis of relapse rates in the four HER2 categories indicated that only 3+ tumors show a significantly poorer prognosis, in both node-positive and node-negative subgroups; however, when patients who underwent invasive surgery are considered, the HER2–2+ patients also showed a significantly increased relapse rate as compared to negative cases, consistent with a stimulation of tumor cells by growth factors released at the time of surgery. Analysis of relapse rates according to type of therapy confirms the unresponsiveness to tamoxifen but sensitivity to chemotherapy, in particular taxanes, of HER2-positive tumors. Indeed, HER2-positive tumors were found to have a significantly better prognosis than HER2-negative when treated with taxanes. Conclusions: The present analysis conducted in a very large series of HER2-positive cases suggests innovative findings that can help optimization of treatment strategy for patients with HER2-positive breast cancer. No significant financial relationships to disclose.

Sign in / Sign up

Export Citation Format

Share Document